Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 17/20 | 0.52 |
| ▸ | CA1 | P00915 | 17/20 | 0.52 |
| ▸ | CA2 | P00918 | 17/20 | 0.52 |
| ▸ | CA9 | Q16790 | 14/20 | 0.52 |
| ▸ | CA7 | P43166 | 12/20 | 0.52 |
| ▸ | CA4 | P22748 | 4/20 | 0.51 |
| ▸ | CA5A | P35218 | 4/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257976 | 0.90 | CA2 (0.54) | CA12CA1CA2CA9CA7 | |
| SCHEMBL22079893 | 0.89 | CA12 (0.49) | CA12CA1CA2CA9CA7 | |
| SCHEMBL24257959 | 0.88 | ALDH1A1 (0.49) | CA12CA1CA2CA9CA7 | |
| SCHEMBL24257974 | 0.84 | CA2 (0.58) | CA12CA1CA2CA9CA7 | |
| SCHEMBL31682092 | 0.79 | ITGB1 (0.47) | CA12CA1CA2CA9CA7 | |
| SCHEMBL31682116 | 0.79 | ITGB1 (0.47) | CA12CA1CA2CA9CA7 | |
| SCHEMBL31682079 | 0.79 | ITGB1 (0.47) | CA12CA1CA2CA9CA7 | |
| SCHEMBL22106138 | 0.78 | CA12 (0.43) | CA12CA1CA2CA9CA7 | |
| SCHEMBL24257965 | 0.74 | CA2 (0.52) | CA12CA1CA2CA9CA7 | |
| SCHEMBL23343670 | 0.73 | CA2 (0.61) | CA12CA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048968-A1 | INSULIN CONJUGATES | SANOFI (FR) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048968-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | CA12 453/4885CA1 1162/4885CA2 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.